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Background: Patients scheduled for transcatheter aortic valve implantation (TAVI) have advanced age, 
with estimated more than 30% of patients with an indication for oral anticoagulation therapy due to 
atrial fibrillation (AF). Dual antiplatelet therapy after TAVI has been historically considered as a stand-
ard approach, with current guidelines supporting the use of oral anticoagulation monotherapy with 
vitamin K antagonists (VKA) in patients requiring stroke protection in atrial fibrillation.1 Direct oral 
anticoagulants (DOACs) are being currently investigated as monotherapy in patients with AF after 
TAVI, with conflicting results among different agents.
Patients and Methods: We analyzed 151 consecutive patients who underwent TAVI procedure in our 
institution from 2013 to 2021.
Results: There were 67 (44%) patients with AF (paroxysmal AF in 17 (25%) patients) that underwent TAVI 
procedure. Their median age was 80 years, 24% had diabetes mellitus, 30% had concomitant coronary 
artery disease, and their median CHA2DS2Vasc score was 5 (high thrombotic risk). Pre-procedural an-
ticoagulation therapy was AVK in 34 (51%), DOACs in 18 (27%), and the remaining 22% of patients were 
taking ASA or clopidogrel. Early post-procedural anticoagulation therapy was AVK in 44 (67%), DOACs 
in 7 (12%), with antiplatelet therapy in 14 (21%) of patients. One patient with AF had post-procedural 
stroke, with no cases of post-procedural stroke among non-AF group. Their in-hospital mortality was 
3.4%, in comparison to 2.7% in patients without AF. After 2017, all patients with AF were anticoagulated 
with AVK or DOAC after TAVI. After 2019, when full percutaneous approach was introduced, 7 patients 
were managed with single DOAC early after TAVI (5 with apixaban, and 2 with rivaroxaban) and had no 
peri-procedural ischemic or bleeding complications related to anticoagulation therapy.
Conclusion: Patients with AF scheduled for TAVI have increased bleeding and thrombotic risk and 
require scrutinized tailoring of anticoagulation and other concomitant therapy. With fast-track trans-
femoral TAVI and full percutaneous approach, early continuation of a single DOAC in optimal dose 
adjusted to age, renal function and other comorbidities appears to be safe and effective and needs to be 
evaluated in a larger cohort of patients.
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